JY
QNCX icon

Jeff Yass’s Quince Therapeutics QNCX Stock Holding History

Jeff Yass’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55
Closed -$1.1K – 14308
2026
Q1 		$1.1K Buy
+55
New +$11K ﹤0.01% 13028
2022
Q4 		– Sell
-323
Closed -$86K – 13436
2022
Q3 		$86K Sell
323
-104
-24% -$39.6K ﹤0.01% 11818
2022
Q2 		$190K Sell
427
-717
-63% -$507K ﹤0.01% 10710
2022
Q1 		$1.42M Sell
1,144
-836
-42% -$1.14M ﹤0.01% 6284
2021
Q4 		$5M Sell
1,980
-130
-6% -$793K ﹤0.01% 3738
2021
Q3 		$38.7M Buy
2,110
+1,196
+131% +$19M 0.01% 1351
2021
Q2 		$9.68M Sell
914
-123
-12% -$1.03M ﹤0.01% 2967
2021
Q1 		$7.47M Buy
1,037
+271
+35% +$1.95M ﹤0.01% 3247
2020
Q4 		$4.25M Buy
766
+736
+2,453% +$6.52M ﹤0.01% 3690
2020
Q3 		$295K Buy
+30
New +$273K ﹤0.01% 8740

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's QNCX Position: Q2 2026 in Review

Jeff Yass sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 863 shares — an estimated $19.8K sold.

Jeff Yass first reported a position in QNCX in Q1 2021 and held it in 17 quarters. The position peaked at $6.12M in Q4 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Jeff Yass reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 863 Quince Therapeutics shares in Q2 2026, an estimated $19.8K.
  • Jeff Yass first reported a position in Quince Therapeutics in Q1 2021 and held it in 17 quarters.
  • Jeff Yass's Quince Therapeutics position peaked at $6.12M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.